306 related articles for article (PubMed ID: 16977322)
1. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.
Kim WY; Safran M; Buckley MR; Ebert BL; Glickman J; Bosenberg M; Regan M; Kaelin WG
EMBO J; 2006 Oct; 25(19):4650-62. PubMed ID: 16977322
[TBL] [Abstract][Full Text] [Related]
2. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
3. Sprouty2 Protein Regulates Hypoxia-inducible Factor-α (HIFα) Protein Levels and Transcription of HIFα-responsive Genes.
Hicks KC; Patel TB
J Biol Chem; 2016 Aug; 291(32):16787-801. PubMed ID: 27281823
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
5. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
6. Regulation of gene expression by the hypoxia-inducible factors.
Fedele AO; Whitelaw ML; Peet DJ
Mol Interv; 2002 Jul; 2(4):229-43. PubMed ID: 14993394
[TBL] [Abstract][Full Text] [Related]
7. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.
Yan Q; Bartz S; Mao M; Li L; Kaelin WG
Mol Cell Biol; 2007 Mar; 27(6):2092-102. PubMed ID: 17220275
[TBL] [Abstract][Full Text] [Related]
8. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
9. Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL).
Heir P; Ohh M
Methods Mol Biol; 2016; 1458():87-94. PubMed ID: 27581016
[TBL] [Abstract][Full Text] [Related]
10. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
11. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
12. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.
Kondo K; Kim WY; Lechpammer M; Kaelin WG
PLoS Biol; 2003 Dec; 1(3):E83. PubMed ID: 14691554
[TBL] [Abstract][Full Text] [Related]
14. Suppression of von Hippel-Lindau Protein in Fibroblasts Protects against Bleomycin-Induced Pulmonary Fibrosis.
Zhou Q; Chen T; Zhang W; Bozkanat M; Li Y; Xiao L; van Breemen RB; Christman JW; Sznajder JI; Zhou G
Am J Respir Cell Mol Biol; 2016 May; 54(5):728-39. PubMed ID: 26488390
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
16. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
17. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
Illingworth CJ; Loenarz C; Schofield CJ; Domene C
Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530
[TBL] [Abstract][Full Text] [Related]
18. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Toschi A; Edelstein J; Rockwell P; Ohh M; Foster DA
Oncogene; 2008 Apr; 27(19):2746-53. PubMed ID: 17998935
[TBL] [Abstract][Full Text] [Related]
19. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
